Skip to content

Study · Not a test of the peptide alone · 2018

9 results

Cost-effectiveness and budget impact of liraglutide in type 2 diabetes patients with elevated cardiovascular risk: a US-managed care perspective.

Shah D, Risebrough NA, Perdrizet J, Iyer NN, Gamble C, Dang-Tan T

ClinicoEconomics and outcomes research : CEOR14 Nov 2018Cited by 14 (Europe PMC)

PMID30532570 (opens in a new tab)PMCIDPMC6241540 (opens in a new tab)DOI10.2147/ceor.s180067 (opens in a new tab)PepBankPUB-30532570
Read at sourcePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study9

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone9

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01Computer modelNot a test of Liraglutide aloneIn silicoOther

    In a T2D model, liraglutide predicted 6.3% fewer events than standard care.

    In plain wordsIn a T2D model, liraglutide predicted 6.3% fewer events than standard care.

    Peptide
    Liraglutide
    Outcome
    DecreasePredicted events
    Study

    n: not reported in source

    Cohort state-transition model of T2D with established CVD or elevated cardiovascular risk
    Comparator
    Standard of care
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    Liraglutide patients experienced 6.3% fewer events, had event-related cost-savings of $15,182, gained additional life-years of 0.67 and quality-adjusted life-years (QALYs) of 0.57, and had additional total costs ($60,928) vs SoC.
    1 context sentence
    Summary · context
    A cohort state-transition model (costs and benefits discounted at 3% per year) was used to predict diabetes-related complications and death (CV and all-cause). Events, treatment effects, and discontinuation rates were from LEADER trial; utility and cost data (US$, 2017) were from literature.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02Computer modelNot a test of Liraglutide aloneIn silicoOther

    In a T2D model, liraglutide predicted event-related cost savings of $15,182 versus standard care.

    In plain wordsIn a T2D model, liraglutide predicted event-related cost savings of $15,182 versus standard care.

    Peptide
    Liraglutide
    Outcome
    DecreaseEvent-related cost savings
    Study

    n: not reported in source

    Cohort state-transition model of T2D with established CVD or elevated cardiovascular risk
    Comparator
    Standard of care
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    Liraglutide patients experienced 6.3% fewer events, had event-related cost-savings of $15,182, gained additional life-years of 0.67 and quality-adjusted life-years (QALYs) of 0.57, and had additional total costs ($60,928) vs SoC.
    1 context sentence
    Summary · context
    A cohort state-transition model (costs and benefits discounted at 3% per year) was used to predict diabetes-related complications and death (CV and all-cause). Events, treatment effects, and discontinuation rates were from LEADER trial; utility and cost data (US$, 2017) were from literature.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03Computer modelNot a test of Liraglutide aloneIn silicoOther

    In a T2D model, liraglutide predicted 0.67 additional life-years versus standard care.

    In plain wordsIn a T2D model, liraglutide predicted 0.67 additional life-years versus standard care.

    Peptide
    Liraglutide
    Outcome
    IncreaseLife-years
    Study

    n: not reported in source

    Cohort state-transition model of T2D with established CVD or elevated cardiovascular risk
    Comparator
    Standard of care
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    Liraglutide patients experienced 6.3% fewer events, had event-related cost-savings of $15,182, gained additional life-years of 0.67 and quality-adjusted life-years (QALYs) of 0.57, and had additional total costs ($60,928) vs SoC.
    1 context sentence
    Summary · context
    A cohort state-transition model (costs and benefits discounted at 3% per year) was used to predict diabetes-related complications and death (CV and all-cause). Events, treatment effects, and discontinuation rates were from LEADER trial; utility and cost data (US$, 2017) were from literature.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 04Computer modelNot a test of Liraglutide aloneIn silicoOther

    In a T2D model, liraglutide predicted 0.57 additional quality-adjusted life-years versus standard care.

    In plain wordsIn a T2D model, liraglutide predicted 0.57 additional quality-adjusted life-years versus standard care.

    Peptide
    Liraglutide
    Outcome
    IncreaseQuality-adjusted life-years
    Study

    n: not reported in source

    Cohort state-transition model of T2D with established CVD or elevated cardiovascular risk
    Comparator
    Standard of care
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    Liraglutide patients experienced 6.3% fewer events, had event-related cost-savings of $15,182, gained additional life-years of 0.67 and quality-adjusted life-years (QALYs) of 0.57, and had additional total costs ($60,928) vs SoC.
    1 context sentence
    Summary · context
    A cohort state-transition model (costs and benefits discounted at 3% per year) was used to predict diabetes-related complications and death (CV and all-cause). Events, treatment effects, and discontinuation rates were from LEADER trial; utility and cost data (US$, 2017) were from literature.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  5. 05Computer modelNot a test of Liraglutide aloneIn silicoOther

    In a T2D model, liraglutide predicted $60,928 additional total costs versus standard care.

    In plain wordsIn a T2D model, liraglutide predicted $60,928 additional total costs versus standard care.

    Peptide
    Liraglutide
    Outcome
    IncreaseTotal costs
    Study

    n: not reported in source

    Cohort state-transition model of T2D with established CVD or elevated cardiovascular risk
    Comparator
    Standard of care
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    Liraglutide patients experienced 6.3% fewer events, had event-related cost-savings of $15,182, gained additional life-years of 0.67 and quality-adjusted life-years (QALYs) of 0.57, and had additional total costs ($60,928) vs SoC.
    1 context sentence
    Summary · context
    A cohort state-transition model (costs and benefits discounted at 3% per year) was used to predict diabetes-related complications and death (CV and all-cause). Events, treatment effects, and discontinuation rates were from LEADER trial; utility and cost data (US$, 2017) were from literature.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  6. 06Computer modelNot a test of Liraglutide aloneIn silicoOther

    In a T2D model, liraglutide's incremental cost-effectiveness ratio versus standard care was $106,749/QALY, below the stated willingness-to-pay threshold.

    In plain wordsIn a T2D model, liraglutide's incremental cost-effectiveness ratio versus standard care was $106,749/QALY, below the stated threshold.

    Peptide
    Liraglutide
    Outcome
    Not applicableIncremental cost-effectiveness ratio
    Study

    n: not reported in source

    Cohort state-transition model of T2D with established CVD or elevated cardiovascular risk
    Comparator
    Standard of care
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    Liraglutide was cost-effective with an incremental CE ratio of $106,749/QALY which was below the willingness-to-pay threshold of $150,000/QALY accepted by the Institute of Clinical and Economic Research.
    1 context sentence
    Summary · context
    A cohort state-transition model (costs and benefits discounted at 3% per year) was used to predict diabetes-related complications and death (CV and all-cause). Events, treatment effects, and discontinuation rates were from LEADER trial; utility and cost data (US$, 2017) were from literature.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  7. 07Computer modelNot a test of Liraglutide aloneIn silicoOther

    In a T2D model, liraglutide remained cost-effective versus standard care across sensitivity analyses except when all-cause mortality hazard varied.

    In plain wordsIn a T2D model, liraglutide remained cost-effective versus standard care across sensitivity analyses except when all-cause mortality hazard varied.

    Peptide
    Liraglutide
    Outcome
    MixedSensitivity analysis of cost-effectiveness
    Study

    n: not reported in source

    Cohort state-transition model of T2D with established CVD or elevated cardiovascular risk
    Comparator
    Standard of care
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    Liraglutide was cost-effective across all sensitivity analyses, except when the hazard ratio for all-cause mortality varied.
    1 context sentence
    Summary · context
    A cohort state-transition model (costs and benefits discounted at 3% per year) was used to predict diabetes-related complications and death (CV and all-cause). Events, treatment effects, and discontinuation rates were from LEADER trial; utility and cost data (US$, 2017) were from literature.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  8. 08Computer modelNot a test of Liraglutide aloneIn silicoOther

    In a T2D budget model, liraglutide use with dulaglutide displacement produced annual plan savings of $266,334 and was considered budget neutral.

    In plain wordsIn a T2D budget model, liraglutide use with dulaglutide displacement produced annual plan savings of $266,334 and was considered budget neutral.

    Peptide
    Liraglutide
    Outcome
    DecreasePer-plan annual budget impact
    Study

    n: not reported in source

    Budget impact analysis of a health plan with 1 million members
    Comparator
    Displacement from dulaglutide
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    The budget impact was neutral, with a per-plan-per-year and per-member-per-month cost-savings of $266,334 and $0.02, respectively.
    2 context sentences
    Summary · context
    Additionally, a budget impact analysis was conducted to evaluate the financial impact of liraglutide use in this population, with displacement from dulaglutide, assuming a health care plan with 1 million members.
    Summary · context
    A cohort state-transition model (costs and benefits discounted at 3% per year) was used to predict diabetes-related complications and death (CV and all-cause). Events, treatment effects, and discontinuation rates were from LEADER trial; utility and cost data (US$, 2017) were from literature.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  9. 09Computer modelNot a test of Liraglutide aloneIn silicoOther

    In a T2D budget model, liraglutide use with dulaglutide displacement produced monthly savings of $0.02 per member and was considered budget neutral.

    In plain wordsIn a T2D budget model, liraglutide use with dulaglutide displacement produced monthly savings of $0.02 per member and was considered budget neutral.

    Peptide
    Liraglutide
    Outcome
    DecreasePer-member monthly budget impact
    Study

    n: not reported in source

    Budget impact analysis of a health plan with 1 million members
    Comparator
    Displacement from dulaglutide
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    The budget impact was neutral, with a per-plan-per-year and per-member-per-month cost-savings of $266,334 and $0.02, respectively.
    2 context sentences
    Summary · context
    Additionally, a budget impact analysis was conducted to evaluate the financial impact of liraglutide use in this population, with displacement from dulaglutide, assuming a health care plan with 1 million members.
    Summary · context
    A cohort state-transition model (costs and benefits discounted at 3% per year) was used to predict diabetes-related complications and death (CV and all-cause). Events, treatment effects, and discontinuation rates were from LEADER trial; utility and cost data (US$, 2017) were from literature.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.